Patent · US Active

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

US10000815B2 · kind B2 · utility

0Cited by

9References

32Claims

0Family size

Assignees

The General Hospital Corporation · US
DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

Daphne Winifred Bell · Bethesda, US
Daniel A. Haber · Sharon, US
Pasi Janne · Needham, US
Bruce E. Johnson · Bellevue, US
Thomas J. Lynch · Cheverly, US
Matthew Meyerson · Concord, US
Juan Guillermo Paez · Deán Funes, AR
William R. Sellers · Sharon, US
Jeffrey E. Settleman · Newton, US
Raffaella Sordella · Cold Spring Harbor, US

Key dates

Filing date	Mar 4, 2015
Grant date	Jun 19, 2018
Priority date	—
Expiry date	Mar 4, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.